These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25274953)

  • 1. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration is not related to kidney function in elderly subjects.
    Kocelak P; Olszanecka-Glinianowicz M; Owczarek A; Bozentowicz-Wikarek M; Brzozowska A; Mossakowska M; Skalska A; Wiecek A; Chudek J
    Clin Chem Lab Med; 2015 Apr; 53(5):793-9. PubMed ID: 25274953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma visfatin/nicotinamide phosphoribosyltransferase levels in hypertensive elderly - results from the PolSenior substudy.
    Kocelak P; Olszanecka-Glinianowicz M; Owczarek A; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Zdrojewski T; Grodzicki T; Więcek A; Chudek J
    J Am Soc Hypertens; 2015 Jan; 9(1):1-8. PubMed ID: 25537462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating visfatin/NAMPT, nutritional status and insulin resistance in an elderly population - results from the PolSenior substudy.
    Olszanecka-Glinianowicz M; Owczarek A; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Zdrojewski T; Grodzicki T; Więcek A; Chudek J
    Metabolism; 2014 Nov; 63(11):1409-18. PubMed ID: 25172122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relationship between circulating visfatin/nicotinamide phosphoribosyltransferase, obesity, inflammation and lipids profile in elderly population, determined by structural equation modeling.
    Owczarek AJ; Olszanecka-Glinianowicz M; Kocełak P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Puzianowska-Kuźnicka M; Grodzicki T; Więcek A; Chudek J
    Scand J Clin Lab Invest; 2016 Dec; 76(8):632-640. PubMed ID: 27712122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma visfatin/nicotinamide phosphoribosyltransferase (visfatin/NAMPT) concentration in elderly subjects with metabolic syndrome.
    Kocełak P; Olszanecka-Glinianowicz M; Owczarek AJ; Krupa W; Obirek P; Bożentowicz-Wikarek M; Brzozowska A; Mossakowska M; Zdrojewski T; Skalska A; Więcek A; Chudek J
    Pol Arch Med Wewn; 2015; 125(6):402-13. PubMed ID: 25924024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
    Axelsson J; Witasp A; Carrero JJ; Qureshi AR; Suliman ME; Heimbürger O; Bárány P; Lindholm B; Alvestrand A; Schalling M; Nordfors L; Stenvinkel P
    Am J Kidney Dis; 2007 Feb; 49(2):237-44. PubMed ID: 17261426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship of visfatin/pre-B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipids.
    Chang YC; Chang TJ; Lee WJ; Chuang LM
    Metabolism; 2010 Jan; 59(1):93-9. PubMed ID: 19765775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.
    Yilmaz MI; Saglam M; Carrero JJ; Qureshi AR; Caglar K; Eyileten T; Sonmez A; Cakir E; Yenicesu M; Lindholm B; Stenvinkel P; Axelsson J
    Nephrol Dial Transplant; 2008 Mar; 23(3):959-65. PubMed ID: 17984105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.
    Hsu CY; Huang PH; Chen TH; Chiang CH; Leu HB; Huang CC; Chen JW; Lin SJ
    Am J Hypertens; 2016 Apr; 29(4):528-36. PubMed ID: 26298010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diurnal rhythm of circulating nicotinamide phosphoribosyltransferase (Nampt/visfatin/PBEF): impact of sleep loss and relation to glucose metabolism.
    Benedict C; Shostak A; Lange T; Brooks SJ; Schiöth HB; Schultes B; Born J; Oster H; Hallschmid M
    J Clin Endocrinol Metab; 2012 Feb; 97(2):E218-22. PubMed ID: 22090280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects.
    Goktas Z; Owens S; Boylan M; Syn D; Shen CL; Reed DB; San Francisco S; Wang S
    Mediators Inflamm; 2013; 2013():861496. PubMed ID: 24367155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down-regulated in nonalcoholic fatty liver disease.
    Dahl TB; Haukeland JW; Yndestad A; Ranheim T; Gladhaug IP; Damås JK; Haaland T; Løberg EM; Arntsen B; Birkeland K; Bjøro K; Ulven SM; Konopski Z; Nebb HI; Aukrust P; Halvorsen B
    J Clin Endocrinol Metab; 2010 Jun; 95(6):3039-47. PubMed ID: 20392873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans.
    Laudes M; Oberhauser F; Schulte DM; Freude S; Bilkovski R; Mauer J; Rappl G; Abken H; Hahn M; Schulz O; Krone W
    Horm Metab Res; 2010 Apr; 42(4):268-73. PubMed ID: 20091460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models.
    Mercader J; Granados N; Caimari A; Oliver P; Bonet ML; Palou A
    Horm Metab Res; 2008 Jul; 40(7):467-72. PubMed ID: 18401839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.
    de Boer JF; Bahr MJ; Böker KH; Manns MP; Tietge UJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G196-201. PubMed ID: 19074645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nicotinamide phosphoribosyltransferase/pre-B-cell colony enhancing factor/visfatin plasma levels and clinical outcome in patients with dilated cardiomyopathy.
    Bobbert P; Kühl U; Poller W; Rauch U; Schultheiss HP; Skurk C
    J Card Fail; 2015 Apr; 21(4):330-8. PubMed ID: 25498756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.
    Eyileten T; Sonmez A; Saglam M; Cakir E; Caglar K; Oguz Y; Vural A; Yenicesu M; Yilmaz MI
    Nephrology (Carlton); 2010 Mar; 15(2):225-9. PubMed ID: 20470283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating visfatin level is correlated with inflammation, but not with insulin resistance.
    Oki K; Yamane K; Kamei N; Nojima H; Kohno N
    Clin Endocrinol (Oxf); 2007 Nov; 67(5):796-800. PubMed ID: 17634078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of Nampt/visfatin and high molecular weight adiponectin in response to oral glucose load in obese and lean women.
    Unlütürk U; Harmanci A; Yildiz BO; Bayraktar M
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):469-74. PubMed ID: 19650786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease.
    Moschen AR; Geiger S; Gerner R; Tilg H
    Mutat Res; 2010 Aug; 690(1-2):95-101. PubMed ID: 19583971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.